Pharmaceuticals
* Please select month and year together
Neimeth International Pharmaceuticals PLC reported its financial results for the nine months ended 30 September 2025. Revenue increased 62 percent to N5.01 billion from N3.09 billion in the prior year period. Operating profit rose 120 percent to N1.66 billion. Finance costs grew 198 percent to N1.32 billion. Profit for the […]
Document type: Interim Reports
Published: Oct 30, 2025
Year: 2025
Period: Q3
Pharmaceuticals | Nigeria
May & Baker Nigeria Plc reports interim financial results for the nine-month period ended 30 September 2025. Key financial highlights: Revenue: ₦29.53 billion, compared to ₦21.82 billion in the prior year period. Profit for the period: ₦3.34 billion, compared to ₦1.89 billion in the prior year period. Basic Earnings Per […]
Document type: Interim Reports
Published: Oct 30, 2025
Year: 2025
Period: Q3
Pharmaceuticals | Nigeria
JULI PLC results for the nine months to 30 September 2025 show revenue at ₦383.11 million, a 10% increase year-on-year. The company recorded a net loss of (₦53.66 million) compared to a (₦3.78 million) loss in the prior period. Total assets were ₦166.70 million against total liabilities of ₦168.62 million, […]
Document type: Interim Reports
Published: Oct 30, 2025
Year: 2025
Period: Q3
Pharmaceuticals | Nigeria
Africure Pharmaceuticals Ltd reported its Q1 FY2025-2026 interim financial results for the three months ending 30 June 2025. Total assets decreased to USD 56.74 million from USD 58.44 million, with total equity down to USD 15.01 million. Group revenue was USD 5.71 million, down from USD 6.45 million, resulting in […]
Document type: Interim Reports
Published: Sep 29, 2025
Year: 2026
Period: Q1
Pharmaceuticals | Mauritius
Pharmaceutical leader in Ghana and West Africa, producing and distributing intravenous fluids and injectables with a focus on quality and compliance.
Pharmaceuticals | Ghana
Intravenous Infusions PLC reported total assets of GHS 41,923,511 as of 30 June 2025, a 12% decrease year-on-year. Total liabilities were GHS 26,039,366, an 11% decrease, while total equity decreased to GHS 15,884,145. Revenue for the period was GHS 7,073,903, down 44%, resulting in a gross profit of GHS 2,169,721 […]
Document type: Interim Reports
Published: Sep 9, 2025
Year: 2025
Period: HY
Pharmaceuticals | Ghana
QCIL is Uganda’s leading pharma company, producing affordable, high-quality medicines, driving healthcare innovation, and expanding across Africa.
Pharmaceuticals | Uganda
May 18, 2025 –
Quality Chemical Industries Limited has declared a dividend. The following are the details related to the dividend: Ex-Dividend date 05/08/2025 Record date 07/08/2025 Payment date 14/08/2025 Dividend amount per share 6 UGX
Corporate announcement, Dividends | Uganda
Dannex Ayrton Starwin PLC reports total assets of GHC 108,447,629 and total liabilities of GHC 81,960,052 as of 30th June 2025. Total equity decreased to GHC 26,487,577. Revenue for the six months is GHC 83,104,849, with a net loss after tax of GHC (269,859). Operating profit stood at GHC 3,808,435, […]
Document type: Interim Reports
Published: Aug 5, 2025
Year: 2025
Period: HY
Pharmaceuticals | Ghana
MeCure Industries Plc has reported interim financial results for the six months ended 30 June 2025. Total assets increased to ₦67,503,846 from ₦54,837,886 at year-end 2024. Total liabilities rose to ₦51,411,444 from ₦40,878,879, while total equity grew to ₦16,092,402 from ₦13,959,007. Revenue for the period reached ₦37,262,054, up 118% from […]
Document type: Interim Reports
Published: Jul 30, 2025
Year: 2025
Period: HY
Pharmaceuticals | Nigeria
Neimeth International Pharmaceuticals Plc reported total assets of ₦12.43 billion and total liabilities of ₦10.56 billion as of 30 June 2025. Equity increased to ₦1.87 billion. For the six months ended 30 June 2025, revenue reached ₦2.91 billion, with a profit before taxation of ₦103.88 million. Basic earnings per share […]
Document type: Interim Reports
Published: Jul 31, 2025
Year: 2025
Period: HY
Pharmaceuticals | Nigeria
Africure Pharmaceuticals Ltd reported a revenue increase of 10% to $29.77 million for the year ended 31 March 2025. EBITDA rose 14% to $3.73 million with a margin of 13%. The company recorded a net loss of $2.81 million, resulting in a basic and diluted EPS of -$0.3. Government orders […]
Document type: Abridged Reports
Published: Aug 1, 2025
Year: 2025
Period:
Pharmaceuticals | Mauritius
THE INVESTOR MAILING LIST
The investor mailing list (IML) is an investor relations newsletter focused on African stock markets. The IML has all the essential share trading updates, financial documents, news and corporate announcements. The newsletter currently covers 11 African stock markets and is free.